PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise in early trial for advanced melanoma
Disease control OngoingThis early-phase trial is testing whether adding an experimental drug called VX15/2503 to standard immunotherapies (ipilimumab or nivolumab) can help treat stage IIIB-D melanoma that can be removed by surgery. About 41 participants will receive the drug combination before surgery…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Patient's own immune cells plus drug tested against tough melanoma
Disease control OngoingThis early-stage trial tests whether giving a patient's own lab-grown tumor-fighting immune cells (Lifileucel) together with the immunotherapy drug pembrolizumab can safely shrink advanced melanoma. Only 2 people with stage IIIB-D or IV melanoma took part. The goal is to see if t…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Richard Wu • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Facebook groups aim to boost skin checks in young melanoma families
Knowledge-focused OngoingThis study looks at whether Facebook groups can help young people diagnosed with melanoma (ages 18-39) and their close relatives do more skin exams and sun protection. About 1,160 participants will join either a melanoma-focused Facebook group or a healthy lifestyle Facebook grou…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Melanoma survivors: new study tracks immunotherapy side effects
Knowledge-focused OngoingThis study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC